Introduction
============

Rheumatoid arthritis and osteoarthritis each affects a significant proportion of the population and the resulting loss of articular cartilage and inflammation causes severe pain and disability. There are no effective treatments for repair of the damaged articular cartilage in these diseases and while their likely aetiologies are very different, common pathways of degradation are important in both. Cartilage degradation occurs as a result of an imbalance of extracellular matrix proteinases and their inhibitors, in particular the matrix metalloproteinases (MMPs) and the tissue inhibitors of MMPs (TIMPs). Specifically, MMP-2 and -9 have been reported to be elevated in osteoarthritis cartilage \[[@B1],[@B2]\] and within the synovial fluid of patients with rheumatoid arthritis \[[@B3]\], suggesting critical roles for these degradative enzymes in arthritic disease. In addition to its ability to degrade the cartilage matrix directly, MMP-2 plays a significant role in the activation of collagenases that are also strongly implicated in arthritic disease. MMPs and TIMPs, in turn, are regulated via induction of the early response genes c-*fos*and c-*jun*and by proinflammatory cytokines that are known to be involved in arthritic diseases \[[@B4],[@B5]\], such as interleukin-1 and tumour necrosis factor α (TNF-α). TNF-α is capable of inducing cartilage catabolism *in vitro*\[[@B5]\] via increased MMP expression and activation \[[@B4]\] and is elevated in the synovial fluids from patients with arthritic disease \[[@B6],[@B7]\]. It signals via a number of pathways including activation of sphingomyelinases, which degrade the membrane phospolipid sphingomyelin into phosphocholine and ceramide \[[@B8]\]. In turn, ceramide exerts its effects in a variety of ways depending on cell type (for a review see \[[@B9]\]), but several studies have implicated this second messenger in the regulation of MMPs \[[@B10]-[@B13]\]. In fibroblasts, the cell-permeable ceramide analogue C~2~-ceramide has been shown to stimulate mRNA expression for MMP-1 and MMP-3 through activation of signal pathways that ultimately lead to the induction of c-*jun*and c-*fos*and AP-1-dependent transcription of MMP genes \[[@B10]\]. In addition, triggering of the ceramide pathway in human keratinocytes results in overexpression of MMP-9 \[[@B11]\]. Recently it was shown that ceramide stimulates proteoglycan degradation and mRNA expression of MMP-1, -3, and -13 in rabbit articular cartilage \[[@B12],[@B13]\]. This finding is important because it establishes a direct link between cartilage degradation and the ceramide pathway.

Previously, we have shown that the protein kinase R (PKR)-activating protein (PACT) \[[@B14]\] is up-regulated in regions of cartilage that subsequently develop osteoarthritis-like changes *in vivo*\[[@B15]\] and that PACT and PKR are involved in the TNF-α signalling pathway in articular chondrocytes \[[@B16]\]. The PKR pathway is also known to be activated by the sphingolipid ceramide \[[@B17]\]. This has led us to the hypothesis that TNF-α induces MMP expression in chondrocytes via ceramide-mediated activation of PKR. In the current study we have therefore investigated the role of TNF-α, the cell-permeable ceramide analogue C~2~-ceramide, and PKR in a well-characterised *in vitro*model of articular cartilage degradation \[[@B18]\]. We have used this model to activate degradative pathways in otherwise healthy cartilage to reveal potential signalling mechanisms that may be important in arthritic disease.

Materials and methods
=====================

Materials
---------

All chemicals were obtained from Sigma (Poole, UK) unless otherwise stated and were of analytical grade. Recombinant human cytokines were purchased from Peprotech EC Ltd (London, UK). Culture medium consisted of Dulbecco\'s Modified Eagle\'s Medium with Glutamax-I (DMEM; Gibco BRL, Paisley, UK) containing 10 IU penicillin and 10 μg/ml streptomycin.

In vitro cartilage samples
--------------------------

Cartilage was taken from the metacarpophalangeal joint of 7-day-old bovine calves within 12 hours of slaughter using a scalpel and full-depth cartilage explants (20--70 mg) cultured overnight at 37°C in a humidified atmosphere of 5% CO~2~, 95% air, in 1 ml of DMEM supplemented with 10% fetal calf serum (FCS). DMEM containing FCS was removed and explants were incubated overnight in serum-free DMEM with insulin--transferrin--sodium selenite liquid supplement; they were then cultured in the presence of TNF-α (20--100 ng/ml) or cell-permeable C~2~-ceramide (10--100 μM) (Tocris, Bristol, UK) for 24 hours. These concentrations of TNF-α and C~2~-ceramide are known to stimulate catabolism in cartilage \[[@B12],[@B13],[@B18]\]. To inhibit the activation of PKR, 2-aminopurine (2-AP) (1--10 mM) was added to duplicate cultures 1 hour before the addition of treatments. This range of concentrations has been shown to inhibit activation of PKR in a number of studies \[[@B19]-[@B21]\] and did not affect chondrocyte viability in explants over 24 hours of culture (data not shown). Untreated explants or explants treated with 2-AP only served as controls. At the end of each experiment, explants were snap frozen in liquid nitrogen and media collected for analysis as described below.

Gelatin substrate zymography
----------------------------

MMP-2 and MMP-9 activities were detected in media samples by gelatin substrate zymography as described previously \[[@B22]\]. Briefly, gelatin (porcine skin, BDH, Poole. Dorset, UK) was incorporated into 7.5% (w/v) sodium dodecyl sulfate (SDS)--polyacrylamide gels at a final substrate concentration of 1.0 mg/ml. Media samples (20 μl, diluted 1 : 1 with sample buffer (0.12 M Tris/HCl (pH 6.8), containing 4% (w/v) SDS, 20% (v/v) glycerol, and 0.01% (w/v) bromophenol blue), a recombinant MMP-9 standard (1 μl) (Oncogene, Nottingham, UK), bovine-fibroblast-conditioned medium (5 μl) known to contain MMP-2 activity, and protein molecular weight markers (5 μl; molecular weight 14--200 kDa, BioRad, Hertfordshire, UK) were loaded onto the gels and resolved by electrophoresis. Then the gels were washed, with agitation, in 2.5% (v/v) Triton X-100 for 1 hour with at least three changes of solution and subsequently incubated for 16--20 hours at 37°C in 50 mM Tris/HCl (pH 7.8), containing 50 mM CaCl~2~and 0.5 M NaCl. Gels were stained with Coomassie^®^Brilliant Blue R 250 (2 g/l) in distilled water, methanol, and acetic acid (4.5 : 4.5 : 1) for at least 1 hour and were destained in methanol, acetic acid, water (1 : 0.75 : 8.25) until the zones of proteolysis had cleared. The addition of molecular-weight markers and conditioned media to the gels facilitated identification of the enzymes and allowed comparisons between gels. The relative quantities of proteolytic enzymes were analysed by scanning densitometry (Umax Colour Scanner, GMbH, Willich, Germany) and NIH image software (National Institutes of Health, Bethesda, MD, USA) \[[@B23]\] and expressed as absorbance units per milligram wet weight of explant.

Proteoglycan release
--------------------

Proteoglycan release into the medium of cartilage explant cultures was measured by the dimethylmethylene blue (DMMB) assay for sulfated glycosaminoglycan (sGAG), using chondroitin sulfate C from shark cartilage as a standard, as described previously \[[@B18]\]. After treatment, explants were digested in 300 μg/ml of papain in 20 mM sodium phosphate (pH 6.8), 1 mM EDTA, 2 mM dithiothreitol at 60°C for 1 hour and sGAG was determined as above. Differences in the levels of sGAG associated with culture treatment were expressed as micrograms of GAG per milligram wet weight of cartilage.

Cytotoxicity assay
------------------

Cell death was measured using the CytoTox 96^®^assay (Promega, Southampton, UK). This assay quantitatively measures lactate dehydrogenase present in the culture medium that has been released upon natural lysis of cells during the culture period \[[@B24]\]. Differences in the release of lactate dehydrogenase associated with culture treatment were expressed as absorbance units per milligram wet weight of cartilage.

Statistical analysis
--------------------

Data are presented as mean ± SEM (*n*≥ 4 cartilage explants) of a representative experiment and analysed, where appropriate, by Student\'s unpaired two-sample *t*-test or Mann--Whitney test (MMP-9 data). Differences were considered significant at *P*values less than 0.05. Where significance was not obtained, but the *P*value was considered informative, this is also shown. All experiments were performed three times with similar results.

Results
=======

C~2~-ceramide and TNF-α increase both synthesis and activation of MMP-2 in cartilage explants
---------------------------------------------------------------------------------------------

Articular cartilage explants were cultured in the presence of C~2~-ceramide or TNF-α with and without the addition of the PKR inhibitor 2-AP for 24 hours and media were analysed for MMP-2 and MMP-9 activity by gelatin substrate zymography. The presence of MMP-2 (Fig. [1a](#F1){ref-type="fig"}) and of MMP-9 (Fig. [1b](#F1){ref-type="fig"}) was confirmed by comparisons with standards known to contain both enzymes. An additional proteolytic band was detected that appeared to be increased by TNF-α treatment and migrated at a molecular weight previously reported to be a rat/murine-specific glycosylated form of MMP-2 \[[@B25]\].

The relative levels of MMP-2 were determined by scanning densitometry of the zymograms (Fig. [2a](#F2){ref-type="fig"}). C~2~-ceramide (50 μM) treatment of cartilage explants resulted in a significant release of both pro- (15.8 ± 1.8; *P*= 0.004) and active (3.4 ± 1.0; *P*= 0.036) MMP-2 into the culture medium over 24 hours in comparison with basal levels produced by unstimulated control explants (8.2 ± 1.0 and 1.4 ± 0.3 respectively). TNF-α (100 ng/ml) treatment resulted in a small, but not significant, increase in levels of proMMP-2 and active MMP-2 in the media.

C~2~-ceramide-induced regulation of MMP-2 is abrogated by inhibition of PKR
---------------------------------------------------------------------------

To determine a role for PKR in ceramide-induced regulation of MMP-2, we treated explant cultures with C~2~-ceramide in the presence of the PKR inhibitor 2-AP. With the addition of 10 mM 2-AP, the C~2~-ceramide-induced increase in proMMP-2 (15.8 ± 1.8) was significantly reduced (10.6 ± 0.9; *P*= 0.029) to near basal levels (8.2 ± 1.0) and activation of MMP-2 was completely abolished (Fig. [2a](#F2){ref-type="fig"}). A reduction in the activation of MMP-2 was also observed when 2-AP was added to explants treated with TNF-α, although this was not statistically significant (*P*= 0.109). Addition of 2-AP (1, 5, or 10 mM) to control cultures alone had no significant effect on MMP-2 (data not shown).

*De novo*synthesis and activation of MMP-9 is regulated by PKR
--------------------------------------------------------------

The relative levels of MMP-9 were determined by scanning densitometry (Fig. [2b](#F2){ref-type="fig"}). A two-fold increase in the production (*P*= 0.196) and activation (*P*= 0.123) of MMP-9 was observed in cartilage explants stimulated with TNF-α (100 ng/ml) in comparison with levels produced by unstimulated control cultures. C~2~-ceramide (50 μM) had no effect on the levels of MMP-9 produced by cartilage explants. However, in contrast, the addition of 2-AP (10 mM) to explant cultures completely abolished the production and activation of MMP-9 irrespective of ceramide or TNF treatment. Addition of 2-AP (1, 5, or 10 mM) to control cultures alone had no significant effect on MMP-9 (data not shown).

Treatment with TNF-α or C~2~-ceramide increases the release of proteoglycan from bovine articular cartilage
-----------------------------------------------------------------------------------------------------------

An increase in sGAG release from cartilage explants was observed following 24 hours of treatment with 50 ng/ml TNF-α (1.78 ± 0.5; *P*= 0.06), which was highly significant at 100 ng/ml TNF-α (2.44 ± 0.5; *P*\< 0.001) in comparison with release from control cultures (0.73 ± 0.07) (Fig. [3a](#F3){ref-type="fig"}).

The release of sGAG into the medium increased 1.5-fold after treatment with C~2~-ceramide at 10 μM (*P*= 0.092) and 50 μM (*P*= 0.05) and two-fold with C~2~-ceramide at 100 μM (*P*= 0.029) (Fig. [3b](#F3){ref-type="fig"}).

2-aminopurine inhibits proteoglycan release from bovine articular cartilage
---------------------------------------------------------------------------

A role for PKR in C~2~-ceramide- and TNF-α-induced proteoglycan release was examined using the PKR inhibitor 2-AP. Control cultures were treated with 2-AP alone to determine the effects of the inhibitor on basal sGAG release (Fig. [4a](#F4){ref-type="fig"}). No effect was seen at 1 and 5 mM 2-AP. However, a two-fold inhibition of GAG release occurred when control cultures were treated with 10 mM 2-AP (*P*= 0.01).

A concentration of 1 mM 2-AP was therefore subsequently used to determine whether inhibition of PKR can abrogate the effects of ceramide or TNF-α on GAG release. The addition of 2-AP (1 mM) to explants 1 hour before treatment with TNF-α (100 ng/ml) significantly inhibited sGAG release into the medium (2-AP 1.03 ± 0.5 vs TNF-α 2.44 ± 0.5; *P*= 0.027) (Fig. [4b](#F4){ref-type="fig"}). A significant inhibition of sGAG release was also observed when explants were incubated with 2-AP (1 mM) before the addition of 100 μM C~2~-ceramide (2-AP 0.65 ± 0.14 vs ceramide 0.82 ± 0.1; *P*= 0.005) (Fig. [4c](#F4){ref-type="fig"}). These concentrations of TNF-α and C~2~-ceramide were chosen because they stimulated the largest proteoglycan release (Fig. [3](#F3){ref-type="fig"}).

TNF-α and C~2~-ceramide-induced increases in cartilage proteoglycan are PKR dependent
-------------------------------------------------------------------------------------

The amount of sGAG remaining within the cartilage explant after 24 hours of treatment with TNF-α and C~2~-ceramide in the presence and absence of 2-AP was determined by papain digestion and DMMB assay (Fig. [5](#F5){ref-type="fig"}). Interestingly, over this period, both TNF-α and C~2~-ceramide treatment resulted in a small (1.3-fold, *P*= 0.02, and 1.8-fold, *P*= 0.003, respectively) but significant increase in the sGAG content of the cartilage explants. Treatment with 2-AP alone (1 mM) had no effect on the amount of sGAG left within the explant and so this concentration was used to determine whether inhibition of PKR can abrogate the effect of TNF-α or C~2~-ceramide. The addition of 2-AP (1 mM) to explants 1 hour before the addition of TNF-α or C~2~-ceramide blocked their effect on sGAG synthesis within the cartilage.

TNF-α and C~2~-ceramide induce chondrocyte cell death via a mechanism involving PKR
-----------------------------------------------------------------------------------

The viability of articular cartilage explants after treatments was assessed by quantitatively measuring lactate dehydrogenase released into the medium, reflecting cell lysis during the culture period. Treatment of cartilage explants with 100 ng/ml TNF-α resulted in a 4.5-fold increase (*P*= 0.058) in cell death in comparison with control explants (Fig. [6a](#F6){ref-type="fig"}). The addition of 2-AP (10 mM) 1 hour before the treatment of cartilage with TNF-α (100 ng/ml) significantly inhibited TNF-α-induced cell death (5.6-fold; *P*= 0.002) and appeared to promote cell survival in comparison with levels of cell death in untreated controls (*P*= 0.032).

C~2~-ceramide induced a 1.7-fold loss of cell viability at 50 μM (*P*= 0.141) (Fig. [6b](#F6){ref-type="fig"}). This loss became significant at 100 μM of C~2~-ceramide (*P*= 0.014) (data not shown). The addition of 2-AP (1 mM) before the addition of C~2~-ceramide abrogated the effect on cell death induced by C~2~-ceramide (2.3-fold; *P*= 0.05) and again appeared to promote cell survival.

Discussion
==========

PKR is a serine/threonine protein kinase that can phosphorylate a limited number of cellular proteins, including the eukaryotic initiation factor 2α (eIF2α), resulting in a block on translation. Present at low levels in all cells, PKR is activated by double-stranded RNA, other polyanionic molecules such as heparin, and the protein activator PACT, and has been shown to be important in transcriptional pathways activated by specific cytokines \[[@B21],[@B26]\], growth factors \[[@B27]\], and extracellular stresses \[[@B28]\]. PKR is involved in a number of cellular responses, including signal transduction, differentiation, and apoptosis \[[@B29]-[@B31]\], that may be involved in cartilage degradation. In the current study, we used the nucleoside analogue 2-AP as an inhibitor of PKR to investigate the role of PKR in the TNF-α- and ceramide-signalling pathways in cartilage degradation. The use of 2-AP as an inhibitor of PKR has been widely reported and there remains little doubt as to the importance of this compound in identifying PKR-dependent pathways in many cell types \[[@B17],[@B19]-[@B21],[@B32]\].

Since PKR has been shown to mediate TNF-α signalling in other cell types, and we had detected an up-regulation of PACT at the onset of osteoarthritis \[[@B15]\], we investigated whether PKR mediates TNF-α-induced degradative pathways in chondrocytes. Our data demonstrate that TNF-α treatment of bovine cartilage explants resulted in a small increase in the expression and activation of MMP-2 and -9. The low level of expression of MMP-9 within our control explants may represent activation of stress response pathways in chondrocytes that have been disrupted at the explant edge, since MMP-9 is not constitutively expressed in chondrocytes and its presence usually represents a degradative or diseased state \[[@B1]\]. The complete loss of expression of both pro- and active MMP-9 in the presence of 2-AP is an interesting finding and suggests that PKR may be a critical regulator of TNF/ceramide induced MMP-9 expression, although this will require further investigation. Inactivation of PKR signalling, therefore, due to TNF/ceramide is likely to abrogate MMP-9 expression below control levels. This regulation of MMP-9 may be through the nuclear factor κB (NFκB) response element in the promoter region of its gene, since NFκB is known to be a transcriptional activator of MMP expression in chondrocytes \[[@B33],[@B34]\] and PKR is known to mediate TNF-α activation of NFκB in a number of cell types \[[@B21],[@B26]\].

TNF-α signalling has been linked to the ceramide pathway in other cell types \[[@B9]\] and ceramide has been shown to increase MMP expression and activation in rabbit cartilage \[[@B12],[@B13]\]. Importantly, binding of TNF-α to its cell-surface receptor (TNF-R55) activates neutral sphingomyelinase, which in turn releases ceramide as a second messenger \[[@B10]\]. TNF-R55 is known to be increased in arthritic disease \[[@B5]\]. We therefore tested whether the catabolic effects of C~2~-ceramide are also mediated through PKR in cartilage. Our studies show that C~2~-ceramide increased pro- and active MMP-2 and -9 in bovine cartilage explants and that this effect was significantly diminished (MMP-2) or completely abolished (MMP-9) by treatment with the PKR inhibitor 2-AP. The mechanism of MMP-2 activation observed in our study remains to be elucidated, but involvement of membrane type 1 MMP (MT1-MMP) seems likely, given that previous studies in hepatic myofibroblasts show that ceramide induces apoptosis and MMP-2 activation through increased MT1-MMP expression \[[@B35]\]. In addition, studies within our own laboratory suggest that C~2~-ceramide treatment of chondrocytes increases levels of MT1-MMP (data not shown). The increased expression and activation of MMP-2 and -9, induced by C~2~-ceramide treatment of chondrocytes, is a novel finding and the significant inhibitory effects of 2-AP provide compelling evidence that PKR is a critical mediator of this response in chondrocytes. Studies are being carried out to determine whether the effects of inhibiting PKR on MMPs are mediated by decreased levels of MT1-MMP or increased levels of TIMPs.

Previous work has shown that treatment of cartilage explants with TNF-α \[[@B36]\] or ceramide \[[@B12],[@B13]\] results in proteoglycan release. Our data confirmed this in bovine cartilage explants, in which either TNF-α or ceramide treatment for 24 hours significantly enhanced proteoglycan release. Somewhat surprisingly, exposure to TNF/ceramide over 24 hours resulted in an increase in the amount of sGAG left within the cartilage, a finding that is suggestive of an anabolic response. Previous studies have shown that exposure to TNF-α or C~2~-ceramide over periods of 3 days or longer results in a net loss of proteoglycan from the cartilage, which is reflected in the increased levels found within the culture medium \[[@B13],[@B18]\]. The short-term period of culture used in this study may reflect events that occur in the early stages of osteoarthritis where, as a response to damaged matrix, chondrocytes show enhanced production of collagen and proteoglycans \[[@B37]\].

Both TNF-α- and C~2~-ceramide-induced proteoglycan release from, and synthesis within, the explants was significantly reduced by treatment with the PKR inhibitor 2-AP at a concentration (1 mM) that does not affect constitutive proteoglycan release/synthesis. This suggests a novel role for PKR in proteoglycan metabolism in chondrocytes. Treatment of cartilage explants with a higher concentration of 2-AP (10 mM), in the absence of other treatments, blocked basal sGAG release without affecting cell viability. Since 10 mM 2-AP did not affect basal levels of MMP production, sGAG release must be due to the activity of alternative enzymes such as the aggrecanases ADAMTS4 and 5. Here we have shown a novel mechanism for proteoglycan catabolism involving PKR that may be important in cartilage degradation. Others have shown that ceramide stimulates aggrecanase-mediated degradation of proteoglycans in articular cartilage, but the mechanism of action remains unknown \[[@B13]\]. Our future studies will therefore investigate whether this occurs via the PKR signalling pathway.

In the current study, we aimed to determine whether TNF-α and C~2~-ceramide can induce cell death in our *in vitro*model of cartilage degradation and whether any such effect is mediated by PKR in chondrocytes. Changes in chondrocyte proliferation and viability are thought to be important in arthritic disease (for a review see \[[@B38]\]) and in animal models of osteoarthritis \[[@B39]\], although the role of apoptosis in arthritis remains controversial. In other cell types, PKR activation has been reported to mediate TNF-α- and ceramide-induced apoptosis \[[@B17],[@B40]-[@B42]\]. We show that both TNF-α and C~2~-ceramide increase chondrocyte death and that this death can be significantly reduced by the addition of 2-AP, confirming a role for PKR in this event. Previous studies have shown that TNF-α treatment of primary chondrocytes and chondrocyte cell lines results in increased apoptosis and caspase activity \[[@B43],[@B44]\]. Since we have previously shown that TNF-α increases PACT protein expression and phosphorylation of PKR and eIF2α in chondrocytes \[[@B16]\] and that this is known to trigger the apoptotic pathway in other cell types \[[@B40],[@B41],[@B45]\], it is tempting to speculate that the cell death observed in this current study is due to apoptosis. This will be confirmed in future studies.

Conclusion
==========

Our data have shown that PKR potentially is an important mediator of degradative and death pathways in chondrocytes. We hypothesise that the TNF-α signalling pathway depicted in Fig. [7](#F7){ref-type="fig"} that has been elucidated for other cell types also operates in chondrocytes. Since both the expression/activation of degradative enzymes and the number of chondrocytes committed to cell death are important determinants of cartilage integrity, our results suggest a pivotal role for the PKR pathway in arthritic disease onset and progression that requires further investigation.
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Figures and Tables
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![Detection of **(a)**MMP-2 and **(b)**MMP-9 activity in media collected from bovine articular cartilage explants treated with TNF-α or C~2~-ceramide for 24 hours. Medium was collected 24 hours after treatment of explants with 100 ng/ml TNF-α or 50 μM C~2~-ceramide in the presence or absence of the PKR inhibitor 2-AP (10 mM) and analysed by gelatin substrate zymography. A standard known to contain either MMP-2 or MMP-9 was included (Std). An unidentified enzyme is indicated by \'?\'. 2-AP, 2-aminopurine; MMP, matrix metalloproteinase; TNF, tumour necrosis factor.](ar1024-1){#F1}

![Quantitative analysis of **(a)**MMP-2 and **(b)**MMP-9 synthesis by bovine articular cartilage. Medium was collected 24 hours after treatment of explants with 100 ng/ml TNF-α or 50 μM C~2~-ceramide in the presence or absence of 2-AP (10 mM) and analysed by gelatin substrate zymography. The area (absorbance units) of substrate gel cleared by proMMP-9 and active MMP-9 was measured by scanning densitometry. Each area obtained was related to the gel clearance obtained with the fibroblast-conditioned-medium standard in order to facilitate comparisons between gels. Data shown are arbitrary units per milligram of wet weight of tissue and are expressed as means ± SEM. \*Significantly different from control explants at *P*\< 0.05; \*\**P*\< 0.01. 2-AP, 2-aminopurine; MMP, matrix metalloproteinase; TNF, tumour necrosis factor.](ar1024-2){#F2}

![Treatment with TNF-α or ceramide induces proteoglycan release from articular cartilage. Cartilage explants were cultured for 24 hours in the presence of **(a)**TNF-α (0--100 ng/ml) or **(b)**C~2~-ceramide (0--100 μM) and media were analysed for release of sulfated GAGs by dimethylmethylene blue assay. Differences in the release of sGAG associated with culture treatment are expressed as micrograms GAG per milligram wet weight of cartilage. \*Significantly different from untreated, control explants at *P*\< 0.05; \*\**P*\< 0.001. sGAG, sulfated glycosaminoglycan; TNF, tumour necrosis factor.](ar1024-3){#F3}

![The PKR inhibitor 2-AP blocks both basal and TNF-α and C~2~-ceramide-induced proteoglycan release from articular cartilage. Bovine articular cartilage explants were cultured for 24 hours in the presence of **(a)**various concentrations of 2-AP (0--10 mM) alone, **(b)**TNF-α (100 ng/ml) with or without 2-AP (1 mM) or **(c)**C~2~-ceramide (100 μM) with or without 2-AP (1 mM). Medium was analysed for release of sGAGs by dimethylmethylene blue assay, expressed as micrograms of glycosaminoglycan released per milligram wet weight of cartilage. \*Significantly different from control explants at *P*\< 0.05; \*\**P*\< 0.01; \*\*\**P*\< 0.001. 2-AP, 2-aminopurine; PKR, protein kinase R; sGAG, sulfated glycosaminoglycan; TNF, tumour necrosis factor.](ar1024-4){#F4}

![The PKR inhibitor 2-AP blocks TNF-α and C~2~-ceramide-induced proteoglycan synthesis. Cartilage explants were cultured for 24 hours in the presence of 2-AP (1 mM) alone, TNF-α (100 ng/ml) with or without 2-AP (1 mM) or C~2~-ceramide (100 μM) with or without 2-AP (1 mM). Explants were digested by papain (300 μg/ml) as described in Materials and methods and the amount of sGAG present determined as described above and expressed as micrograms glycosaminoglycan per milligram wet weight of cartilage. \*Significantly different from control explants at *P*\< 0.05; \*\* *P*\< 0.01. 2-AP, 2-aminopurine; PKR, protein kinase R; sGAG, sulfated glycosaminoglycan; TNF, tumour necrosis factor.](ar1024-5){#F5}

![TNF-α and C~2~-ceramide induce cell death in articular cartilage via a mechanism involving PKR. Bovine articular cartilage explants were cultured for 24 hours in the presence of **(a)**TNF-α (100 ng/ml) or **(b)**C~2~-ceramide (50 μM). 2-AP (1 or 10 mM) was added 1 hour before the addition of treatments. Viability of explant tissue was determined using the CytoTox 96^®^assay, which quantitatively measures lactate dehydrogenase released into culture media upon cell death during the culture period. Data shown are absorbance units per milligrams of starting tissue and are expressed as means ± SEM. \*Significantly different from control explants at *P*\< 0.05; \*\**P*\< 0.01. 2-AP, 2-aminopurine; PKR, protein kinase R; TNF, tumour necrosis factor.](ar1024-6){#F6}

![The potential role of PKR in cartilage degradation. Results from the current study have led us to hypothesise that TNF-α-induced degradative pathways in cartilage may be mediated via activation of PKR. TNF-α binding to its receptor (TNF-R55) may activate PKR either directly or through ceramide (CER) to increase transcription and activation of MMPs via induction of NFκB and early response genes (c-*fos*and c-*jun*). Activation of PKR and subsequent phosphorylation of eIF2α would lead to an inhibition of protein synthesis and increased apoptosis, which may also affect cartilage integrity. Increased expression and activation of MMPs, in the absence of a corresponding increase in their inhibitors, would shift the balance of homeostasis towards matrix catabolism. AP-1, activator protein-1; eIF2α, eukaryotic initiation factor 2α ; IκBα, inhibitor kappa B alpha; MMP, matrix metalloproteinase; NFκB, nuclear factor κB; P, phosphorylated; PACT, PKR-activating protein; PKR, protein kinase R; TIMP, tissue inhibitors of MMP; TNF, tumour necrosis factor; TNF-R55, tumour necrosis factor receptor-55.](ar1024-7){#F7}
